周三盘中，丹纳赫(DHR)股价大涨5.12%，主要受益于公司发布的强劲财报。
丹纳赫公布的第一季度业绩超出华尔街预期。尽管面临严峻的宏观经济环境，公司表现依然出色。多家券商分析师认为，丹纳赫已做好充分准备应对当前挑战。Leerink Partners表示，丹纳赫是生物工艺工具经常性收入市场的领导者。Evercore ISI指出，公司基本订单势头和积压订单表明订单模式正趋于正常化。
受此影响，多家券商调整了对丹纳赫的目标价。其中，摩根大通将目标价从280美元下调至260美元，Leerink Partners将目标价从225美元上调至230美元，TD Cowen则将目标价从240美元上调至248美元。分析师普遍认为，丹纳赫一季度的强劲表现为整个行业带来了积极信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.